Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
This study has been completed.
Sponsor:
Abbott Medical Optics
Information provided by (Responsible Party):
Abbott Medical Optics
ClinicalTrials.gov Identifier:
NCT00747227
First received: September 3, 2008
Last updated: October 6, 2011
Last verified: October 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and effectiveness of a new investigational modified light transmission monofocal intraocular lens compared to a conventional intraocular lens (IOL).
| Condition | Intervention | Phase |
|---|---|---|
|
Cataract |
Device: modified light transmission intraocular lens Device: monofocal acrylic intraocular lens |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Clinical Evaluation of a Modified Light Transmission IOL |
Resource links provided by NLM:
Further study details as provided by Abbott Medical Optics:
Primary Outcome Measures:
- Best Corrected Distance Visual Acuity [ Time Frame: One year ] [ Designated as safety issue: No ]Snellen Equivalent visual acuity of 20/40 or better
- Uncorrected Distance Visual Acuity [ Time Frame: One Year ] [ Designated as safety issue: No ]Snellen Equivalent of 20/40 or better at one year
Secondary Outcome Measures:
- Contrast Sensitivity [ Time Frame: 4-6 months ] [ Designated as safety issue: No ]Contrast sensitivity is the measurement of how faded an image may become before it can clearly be seen. Contrast sensitivity was measured in photopic and mesopic conditions at the following spatial frequencies: 3.0, 6.0, 12.0, and 18 cpd (cycles per degree). Contrast sensitivity is measured in log units. A higher value for the logarithmic units translates to better contrast sensitivity.
- Subject Satisfaction - Subjects Satisfied With Overall Eyesight Rated as "Good" or "Excellent". [ Time Frame: One Year ] [ Designated as safety issue: No ]Subjects indicating a subjective response to a multiple choice question, "At the present time, would you say your eyesight using both eyes (with glasses or contact lenses, if you wear them) is excellent, good, fair, poor, or very poor or are you completely blind?", on a multi-item questionnaire administered by interviewer to determine subject satisfaction with their overall visual outcome at the one year visit.
| Enrollment: | 250 |
| Study Start Date: | December 2006 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ZV9003
modified light transmission intraocular lens
|
Device: modified light transmission intraocular lens
violet visible light blocking acrylic intraocular lens
Other Name: ZV9003
|
|
Active Comparator: ZA9003
monofocal acrylic intraocular lens
|
Device: monofocal acrylic intraocular lens
conventional hydrophobic acrylic intraocular lens
Other Name: ZA9003
|
Detailed Description:
The investigational IOL will be found to be safe and effective with respect to visual acuity, color vision, contrast sensitivity and complications and will be similar to results for the ZA9003 control eyes. Complication rates and adverse event rates will be within the FDA grid for posterior chamber IOLs.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Age 18 years of age or older
- Bilateral cataracts for which phacoemulsification extraction and posterior IOL implantation has been planned
- Visual potential in both eyes of 20/30 Snellen or better after cataract removal and IOL implantation
- Preoperative corneal astigmatism of 1.5 diopters or less
Exclusion Criteria:
- Use of systemic or ocular medications that may affect vision
- Uncontrolled systemic or recurrent ocular disease
- Requiring an intraocular lens <15.0 or >26.0 diopters
- Abnormal results with the Farnsworth-Munsell D-15 and/or Ishihara color plates
- History of ocular trauma or prior ocular surgery
- Known pathology that may affect visual acuity or visual field
- Corneal abnormalities
- Pupil abnormalities
- Capsule or zonular abnormalities
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00747227
Locations
| United States, Arizona | |
| Patrick Aiello, M.D. | |
| Scottsdale, Arizona, United States, 85054 | |
| United States, Arkansas | |
| Randall E. Cole, M.D. | |
| Rogers, Arkansas, United States, 72756 | |
| United States, Connecticut | |
| Aron Rose, M.D. | |
| New Haven, Connecticut, United States, 06510 | |
| United States, Minnesota | |
| Y. Ralph Chu, M.D. | |
| Bloomington, Minnesota, United States, 55420 | |
| United States, Missouri | |
| Steven Silverstein, M.D. | |
| Kansas City, Missouri, United States, 64133 | |
| United States, Oregon | |
| Jon-Marc Weston, M.D. | |
| Roseburg, Oregon, United States, 97470 | |
| United States, Pennsylvania | |
| William Christie, M.D. | |
| Cranberry Township, Pennsylvania, United States, 16066 | |
| Mark Blecher, M.D. | |
| Philadelphia, Pennsylvania, United States, 19148 | |
| United States, Rhode Island | |
| Robert L. Bahr, M.D. | |
| Providence, Rhode Island, United States, 02906 | |
| United States, South Dakota | |
| Vance Thompson, M.D. | |
| Sioux Falls, South Dakota, United States, 57105 | |
| United States, Washington | |
| Jay Rudd, M.D. | |
| Lacey, Washington, United States, 98503 | |
Sponsors and Collaborators
Abbott Medical Optics
Investigators
| Principal Investigator: | Roger F. Steinert, M.D. | University of California, Irvine, Dept. of Ophthalmology |
More Information
No publications provided
| Responsible Party: | Abbott Medical Optics |
| ClinicalTrials.gov Identifier: | NCT00747227 History of Changes |
| Other Study ID Numbers: | BBLK-102-PRSM |
| Study First Received: | September 3, 2008 |
| Results First Received: | March 4, 2011 |
| Last Updated: | October 6, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Abbott Medical Optics:
|
cataract monofocal intraocular lens acrylic |
Additional relevant MeSH terms:
|
Cataract Lens Diseases Eye Diseases |
ClinicalTrials.gov processed this record on May 16, 2013